Agenus Inc
AGEN
Market Cap$130.5M
Close$
$-6.07
227.5% downside
Current Fair Value
227.5% downsideOvervalued by 227.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $130.50 Million |
|---|---|
| Enterprise Value | $230.25 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-10.59 |
| Beta | 1.43 |
| Outstanding Shares | 24,469,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.61 |
|---|---|
| PEG | 1.03 |
| Price to Sales | 1.19 |
| Price to Book Ratio | -1.59 |
| Enterprise Value to Revenue | 2.31 |
| Enterprise Value to EBIT | -3.31 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.51 |
| Debt to Equity | -1.9 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Agenus Inc
CEO: Garo Armen Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators , pa...